A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Depression and anxiety disorders are among the most common disorders treated by general practitioners (GPs) in the UK. Since both disorders are associated with a significantly increased risk of suicide, including with antidepressant overdose, the safety of antidepressants in overdose is of paramount importance. Numerous updates relating to antidepressant safety have been issued by regulators in the UK which may have eroded GP confidence in antidepressants. Venlafaxine, a serotonin nor adrenaline reuptake inhibitor (SNRI) had primary care prescribing restrictions placed on it in 2004 due to concerns about cardiotoxicity and mortality in overdose. Although a review of the evidence led to a reversal of the majority of restrictions in 2006, evidence suggests GPs may still be cautious in their prescribing of venlafaxine and possibly other SNRI antidepressants for patients with depression and anxiety disorders. This paper reviews the evidence pertaining to the safety of SNRI antidepressants from a perspective of cardiovascular safety and overdose. The currently available evidence suggests a marginally higher toxicity of venlafaxine in overdose compared with another SNRI duloxetine and the selective serotonin reuptake inhibitors (SSRIs), although this may be related to differential patterns of prescribing in high-risk patients. Based on this review SNRIs have a positive risk benefit profile in the treatment of depression and generalized anxiety disorder in primary care, especially as second-line agents to SSRIs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adult psychiatric morbidity in England, 2007: Results of a household survey
Mcmanus, S., Meltzer, H., Brugha, T., Bebbington, P., & Jenkins, R. (2009) · Unpublished · doi:10.13140/2.1.1563.5205 · Cited by 814
Gibbons, R. D., Brown, C. H., Hur, K., Davis, J. M., & Mann, J. J. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2048 · Cited by 291
Moore, M., Yuen, H. M., Dunn, N., Mullee, M. A., Maskell, J., & Kendrick, T. (2009) · BMJ · doi:10.1136/bmj.b3999 · Cited by 287
Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose
Hawton, K., Bergen, H., Simkin, S., Cooper, J., Waters, K., Gunnell, D., & Kapur, N. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.070219 · Cited by 192 · cited 2×
“In a recent study case fatality indices were calculated for venlafaxine, TCAs and SSRIs using mortality rates and self-poisoning rates from three centres in the UK [Hawton et al. 2010].”
Suicidal antidepressant overdoses: A comparative analysis by antidepressant type
White, N. C., Litovitz, T., & Clancy, C. (2008) · Journal of Medical Toxicology · doi:10.1007/bf03161207 · Cited by 117 · cited 1×
“A hazard index was calculated for each antidepressant using US poison control data (number of major or fatal outcomes per 1000 reported antidepressant ingestions) [White et al. 2008].”
Perahia, D. G. S., Quail, D., Desaiah, D., Montejo, A. L., & Schatzberg, A. F. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.07.001 · Cited by 64 · cited 1×
“…class after SSRI treatment failure may be a more effective strategy than within class switching [Papakostas et al. 2008]and data specifically support the safety and efficacy of switching SSRI treatment failures to SNRIs, such as duloxetine [Perahia et al. 2008, 2009; Romera et al. 2012].”
Cited by
Hickie, I. B., Scott, E. M., Cross, S. P., Iorfino, F., Davenport, T. A., Guastella, A. J., Naismith, S. L., Carpenter, J. S., Rohleder, C., Crouse, J. J., et al. (2019) · Medical Journal of Australia · doi:10.5694/mja2.50383 · Cited by 208
Nelson, J. C., & Spyker, D. A. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050523 · Cited by 67
Li, Y., Li, H.-P., Wu, M.-X., Wang, Q.-Y., & Zeng, X. (2022) · Clinical Neurophysiology · doi:10.1016/j.clinph.2022.07.369 · Cited by 19
Metadata
- Authors
- Taylor, D., Lenox-Smith, A., & Bradley, A.
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2013-01-28
- Volume
- 3
- Issue
- 3
- Pages
- 151-161
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- OpenAlex
- W2135224551
- Cited by
- 35
- References
- 6
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.